Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase
Background COVID-19 pneumonia causes hyperinflammatory response that culminates in acute respiratory syndrome (ARDS) related to increased multiorgan dysfunction and mortality risk. Antiviral-neutralizing immunoglobulins production reflect the host humoral status and illness severity, and thus, immunoglobulin (Ig) circulating levels could be evidence of COVID-19 prognosis. Methods The relationship among circulating immunoglobulins (IgA, IgG, IgM) and COVID-19 pneumonia was evaluated using clinical information and blood samples in a COVID-19 cohort composed by 320 individuals recruited during the acute phase and followed up to 4 to 8 weeks (n = 252) from the Spanish first to fourth waves. Results COVID-19 pneumonia development depended on baseline Ig concentrations. Circulating IgA levels together with clinical features at acute phase was highly associated with COVID-19 pneumonia development. IgM was positively correlated with obesity (ρb = 0.156, P = 0.020), dyslipemia (ρb = 0.140, P = 0.029), COPD (ρb = 0.133, P = 0.037), cancer (ρb = 0.173, P = 0.007) and hypertension (ρb = 0.148, P = 0.020). Ig concentrations at recovery phase were related to COVID-19 treatments. Conclusions Our results provide valuable information on the dynamics of immunoglobulins upon SARS-CoV-2 infection or other similar viruses..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
European journal of medical research - 29(2024), 1 vom: 06. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peraire, Joaquim [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s40001-024-01824-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055434304 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055434304 | ||
| 003 | DE-627 | ||
| 005 | 20240406064745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40001-024-01824-5 |2 doi | |
| 035 | |a (DE-627)SPR055434304 | ||
| 035 | |a (SPR)s40001-024-01824-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Peraire, Joaquim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background COVID-19 pneumonia causes hyperinflammatory response that culminates in acute respiratory syndrome (ARDS) related to increased multiorgan dysfunction and mortality risk. Antiviral-neutralizing immunoglobulins production reflect the host humoral status and illness severity, and thus, immunoglobulin (Ig) circulating levels could be evidence of COVID-19 prognosis. Methods The relationship among circulating immunoglobulins (IgA, IgG, IgM) and COVID-19 pneumonia was evaluated using clinical information and blood samples in a COVID-19 cohort composed by 320 individuals recruited during the acute phase and followed up to 4 to 8 weeks (n = 252) from the Spanish first to fourth waves. Results COVID-19 pneumonia development depended on baseline Ig concentrations. Circulating IgA levels together with clinical features at acute phase was highly associated with COVID-19 pneumonia development. IgM was positively correlated with obesity (ρb = 0.156, P = 0.020), dyslipemia (ρb = 0.140, P = 0.029), COPD (ρb = 0.133, P = 0.037), cancer (ρb = 0.173, P = 0.007) and hypertension (ρb = 0.148, P = 0.020). Ig concentrations at recovery phase were related to COVID-19 treatments. Conclusions Our results provide valuable information on the dynamics of immunoglobulins upon SARS-CoV-2 infection or other similar viruses. | ||
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IgA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IgG |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IgM |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunoglobulins |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a García-Pardo, Graciano |e verfasserin |4 aut | |
| 700 | 1 | |a Chafino, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Botero-Gallego, Maryluz |e verfasserin |4 aut | |
| 700 | 1 | |a Olona, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Espineira, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Reverté, Laia |e verfasserin |4 aut | |
| 700 | 1 | |a Skouridou, Vasso |e verfasserin |4 aut | |
| 700 | 1 | |a Peiró, Óscar M. |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Bertomeu, Fréderic |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a O’ Sullivan, Ciara K. |e verfasserin |4 aut | |
| 700 | 1 | |a Rull, Anna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medical research |d BioMed Central, 2000 |g 29(2024), 1 vom: 06. Apr. |w (DE-627)SPR032589271 |w (DE-600)2129989-4 |x 2047-783X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:06 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40001-024-01824-5 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 06 |c 04 | ||